Recently, Corcept Therapeutics has submitted a new drug application (NDA) to the US FDA for its proprietary selective cortisol regulator, relacorilant, for the treatment of platinum resistant ovarian cancer patients. In addition, the NDA for the treatment of endogenous hypercortisolism (also known as Cushing's syndrome) using relaxorant is currently undergoing FDA review. It is worth mentioning that this therapy has been selected by industry media Evaluation as one of the potential heavyweight therapies for 2025.
The new drug application is mainly based on positive data from the critical Phase 3 ROSELLA trial and Phase 2 trial. In these trials, platinum resistant ovarian cancer patients treated with relaxorant in combination with albumin paclitaxel had better progression free survival (PFS) and overall survival (OS) than those treated with albumin paclitaxel alone, and patients did not require biomarker screening.
Analysis shows that the ROSELLA trial achieved its primary endpoint - significant improvement in progression free survival as assessed by a blinded independent central review (BICR). Compared with monotherapy, the combination therapy of relaxorant and albumin paclitaxel reduced the risk of disease progression by 30% (hazard ratio: 0.70; p=0.0076). The median PFS-BICR of patients in the Relacorilant combination therapy group was prolonged to 6.5 months, while that of patients treated with albumin paclitaxel monotherapy was 5.5 months. In addition, the PFS results evaluated by the researchers were consistent with PFS-BICR, with a hazard ratio of 0.71 (p=0.0030).
In the mid-term analysis of overall survival, adding relaxorant reduced the risk of death for patients by 31% and significantly prolonged their lives. The median OS of the Relacorilant combination therapy group was 16.0 months, while the albumin paclitaxel monotherapy group was 11.5 months (hazard ratio: 0.69; p=0.0121). This therapeutic effect is reflected in all clinically relevant subgroups, including patients with poor prognosis.
Relacorilant is an oral, potentially "first in class" selective glucocorticoid receptor (GR) antagonist that regulates cortisol activity by binding to GR rather than other hormone receptors in the body. Corcept Therapeutics is developing relaxorant for ovarian cancer and various other serious diseases, including endogenous hypercortisolism and prostate cancer.
<Reprinted from WuXi AppTec>







